Mint Tower Capital Management’s AbbVie ABBV Stock Holding History

Mint Tower Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-49,900	Closed	-$8.06M	–	289
2022 Q4	$8.06M	Buy	49,900 +12,900	+35%	+$1.98M	0.72%	26
2022 Q3	$4.97M	Sell	37,000 -100	-0.3%	-$14.3K	0.39%	50
2022 Q2	$5.68M	Buy	37,100 +17,100	+86%	+$2.61M	0.45%	42
2022 Q1	$3.24M	Sell	20,000 -8,800	-31%	-$1.28M	0.3%	58
2021 Q4	$3.9M	Buy	28,800 +10,200	+55%	+$1.2M	0.5%	37
2021 Q3	$2.01M	Buy	18,600 +2,500	+16%	+$286K	0.25%	80
2021 Q2	$1.81M	Sell	16,100 -16,600	-51%	-$1.87M	0.13%	134
2021 Q1	$3.5M	Buy	32,700 +20,700	+173%	+$2.21M	0.33%	37
2020 Q4	$1.27M	Buy	+12,000	New	+$1.15M	0.17%	25
2020 Q2	–	Sell	-39,000	Closed	-$2.93M	–	254
2020 Q1	$2.93M	Sell	39,000 -14,400	-27%	-$1.23M	0.56%	34
2019 Q4	$4.73M	Sell	53,400 -1,600	-3%	-$133K	0.63%	42
2019 Q3	$4.17M	Buy	+55,000	New	+$3.77M	0.6%	35

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Mint Tower Capital Management's ABBV Position: Q4 2022 in Review

Mint Tower Capital Management sold out of AbbVie (ABBV) in Q4 2022, closing a stake of 4,008 shares — an estimated $615K sold.

Mint Tower Capital Management first reported a position in ABBV in Q2 2021 and held it in 3 quarters. The position peaked at $538K in Q3 2022. 3,167 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

Mint Tower Capital Management reported no remaining AbbVie position as of Q4 2022 after selling out during the quarter.
Mint Tower Capital Management sold 4,008 AbbVie shares in Q4 2022, an estimated $615K.
Mint Tower Capital Management first reported a position in AbbVie in Q2 2021 and held it in 3 quarters.
Mint Tower Capital Management's AbbVie position peaked at $538K in Q3 2022.
3,167 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on Mint Tower Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.